A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO | NVO Price Prediction) has been a trailblazer in the GLP-1 drug market, revolutionizing diabetes and obesity treatment with its blockbuster…
Weighing the Options The introduction of Novo Nordisk’s (NYSE:NVO | NVO Price Prediction) Ozempic revolutionized the fight against obesity, shifting the narrative from lifestyle interventions to pharmacological solutions. Glucagon-like peptide-1 (GLP-1) receptor…
Live Updates Tuesday Wrap-up4:27pm ETThe Vanguard S&P 500 ETF closed at 577.35 Tuesday, down 0.5%. Getting the DUKs in a Row12:41pm ETS&P component company Duke Energy (NYSE: DUK | PFE Price Prediction) beat…
Live Updates Conference Cal Starts in 10 Minutes 4:50pm ETWe’ll post a summary of the call later. Simply leave this page open and if you check later a new update with our…
Joel South Danish pharmaceutical giant Novo Nordisk (NYSE:NVO | NVO Price Prediction) is watching its stock plummet 20% in morning trading after slashing its full-year sales and profit outlook for the second time this…
Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no company news. While it is revolutionizing access to healthcare by…
Digging Into the Bargain Bin Investing in beaten-down stocks can be a savvy strategy for long-term wealth creation, as it allows investors to buy high-quality companies at bargain prices. When market sentiment…
If you wish to turn $10,000 into $50,000 by 2035, you’re looking at a 400% gain over a 10-year horizon. In the past decade, the S&P 500 has gained 194%, and the…
The Power of Long-Term Investing Long-term investing is the cornerstone of wealth creation, prioritizing steady growth over fleeting market spikes. Before buying stocks, investors should go into it with the idea of…
Investors usually focus on stocks that already have stellar dividend yields, but your portfolio could also benefit from dividend growers. There are companies with solid fundamentals with a history of growing their…
There’s a well-known saying in the investing world, which advises investors to “sell in May and go away.” Historically, that has been solid advice, based on the typical seasonality of markets and…
Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, marking a 111% increase year-over-year. The company achieved a net income of $49.5 million,…
Joel South Live Updates HIMS forward guidance is exciting 5:02pm ETJoel South HOLY MOLY $HIMS JUST GUIDED TO $6.5B IN 2030 SALES WITH 20% EBITDA MARGINS 😳 pic.twitter.com/9w2fDU8rlQ — Shay Boloor (@StockSavvyShay) May 5,…
Joel South Live Updates S&P 500 Extends Its Winning Streak4:18pm ETThe S&P 500 closed up 0.6% for Tuesday, extending its winning streak to six straight days. Trade Talks Keep S&P 500 Moving Higher1:51pm ET“Ask,…
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn’t guarantee it would be able to continue selling its knockoff…
